Results 21 to 30 of about 4,535 (170)

Paxlovid accelerates cartilage degeneration and senescence through activating endoplasmic reticulum stress and interfering redox homeostasis

Journal of Translational Medicine, 2022
Background The COVID-19 pandemic has become a huge threat to human health, infecting millions of people worldwide and causing enormous economic losses.
Keyu Kong, Yongyun Chang, Hua Qiao, Chen Zhao, Xuzhuo Chen, Kewei Rong, Pu Zhang, Minghao Jin, Jingwei Zhang, Huiwu Li, Zanjing Zhai   +10 more
doaj   +1 more source

Severe HCoV-OC43 Pneumonia in a 25-Year-Old Woman Following Allogeneic Hematopoietic Stem Cell Transplantation. [PDF]

Clin Respir J
This case reports a 25‐year‐old allo‐HCT recipient with severe HCoV‐OC43 pneumonia who responded well to off‐label nirmatrelvir/ritonavir. It is the first such report that show the drug may benefit immunocompromised patients with this infection, though further studies are needed to confirm efficacy.
Zhang M, Tang T, Zheng M, Luo M, Xu Z, Wang G.   +5 more
europepmc   +2 more sources

Safety and Efficacy of Paxlovid in COVID-19 Treatment: A Rapid Review

Health Technology Assessment in Action, 2022
Context: In the first stage of viral replication, COVID-19 may cause a remarkable inflammatory response in patients. Paxlovid is an oral antivirus medicine that functions through the inhibition of one of the essential enzymes to viral replication, called
Mohamad Reza Mobinizadeh, Ali Akbarisari, Alireza Olyaeemanesh, Marita Mohammadshahi, Elham Ahmadnezhad, Parisa Aboee, Zahra Gharib Naseri, Zeinab Fakoorfard, Raheleh Sadeghi   +8 more
doaj   +1 more source

Posterior Reversible Encephalopathy Syndrome in an Older Patient in the COVID-19 and Paxlovid Era

Annals of Internal Medicine: Clinical Cases, 2023
Nirmatrelvir/ritonavir (Paxlovid) has been prescribed increasingly for treatment of COVID-19. Due to ritonavir's inhibition of CYP3A4, there are many medication interactions to consider.
Katharine Rosiene, Minisha Lohani, Mario Gemmato-Valecillos, Cristina Marti-Amarista, Sadia Abbasi   +4 more
doaj   +1 more source

Paxlovid–tacrolimus drug–drug interaction caused severe diarrhea that induced combined diabetic ketoacidosis and a hyperglycemic hyperosmolar state in a kidney transplant patient: a case report

Journal of Medical Case Reports, 2023
Background Transplant recipients are at high risk of coronavirus disease 2019, and a timely supply of antivirals should be prioritized for those patients.
Wei Luo, Yu He, Mao Gang Wei, Guang Bing Lu, Qun Yi   +4 more
doaj   +1 more source

Neutropenia after the coadministration of clozapine and nirmatrelvir-ritonavir in a patient with SARS-CoV-2 infection: A case report with a literature review

Frontiers in Psychiatry, 2022
BackgroundSchizophrenia is considered one of the major risk factors for mortality from SARS-CoV-2 infection. Early antiviral treatment is important to decrease the risk of mortality.
Chun-I Liu, Kah Kheng Goh, Kah Kheng Goh, Kah Kheng Goh, Chun-Hsin Chen, Chun-Hsin Chen, Chun-Hsin Chen   +6 more
doaj   +1 more source

The efficacy of paxlovid in elderly patients infected with SARS-CoV-2 omicron variants: Results of a non-randomized clinical trial

Frontiers in Medicine, 2022
ObjectiveTo evaluate the efficacy of Paxlovid in treating Chinese elder patients infected with SARS-CoV-2 omicron variants.Materials and methodsWe performed a non-randomized, controlled trial in Shanghai, China.
Weijie Zhong, Xiufeng Jiang, Xiaosheng Yang, Tiantong Feng, Zhixin Duan, Wei Wang, Zhaoliang Sun, Lingyan Chen, Xin Nie, Chuanlong Zhu, Wenchuan Zhang, Yi Li   +11 more
doaj   +1 more source

Risks of paxlovid in a heart transplant recipient

The Journal of Heart and Lung Transplantation, 2023
The burden of morbidity and mortality from SARS-CoV-2 infection is especially significant in heart transplant patients who are at higher risk for poor outcomes owing to immunosuppression, blunted response to vaccination, and multiple comorbid conditions.
Kristin Stawiarski, Robin Avery, Sara Strout, Priya Umapathi   +3 more
openaire   +2 more sources

Paxlovid-Induced Symptomatic Bradycardia and Syncope

Cureus, 2023
Paxlovid (nirmatrelvir/ritonavir) is a game changer in the fight against COVID-19 due to its ease of administration and significant benefits of reducing progression to severe COVID-19, hospitalization, and death. Cardiac adverse events such as bradycardia and syncope are not known with this medication.
Ganipisetti, Venu M, Bollimunta, Pratyusha, Maringanti, Sriram   +2 more
openaire   +2 more sources

Serotonin Syndrome Precipitated by Paxlovid Initiation

Cureus, 2023
A female in her early 40s taking buspirone, quetiapine, and daily kratom presented to the emergency department two days after starting a course of Paxlovid for a mild COVID-19 infection with diffuse tremors, ocular clonus, diaphoresis, and confusion consistent with serotonin syndrome (SS).
Nasser, Nicholas G, Welsh, Connor, Mitra, Avir, Swan, Matthew   +3 more
openaire   +2 more sources